CoChat

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Open access

Published version of a preprint

The DOI matches its Crossref record; 67 of the 67 references it cites were found in a registry or an index.

Abstract

Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4 and PD-1 is associated with clinical benefit across tumor types, but also a high rate of immune-related adverse events. Insights into biomarkers and mechanisms of response and toxicity to CICB are needed. To address this, we profiled the blood, tumor and gut microbiome of 77 patients with advanced melanoma treated with CICB, with a high rate of any ≥grade 3 immune-related adverse events (49%) with parallel studies in pre-clinical models. Tumor-associated immune and genomic biomarkers of response to CICB were similar to those identified for ICB monotherapy, and toxicity from CICB was associated with a more diverse peripheral T-cell repertoire. Profiling of gut microbiota demonstrated a significantly higher abundance of Bacteroides intestinalis in patients with toxicity, with upregulation of mucosal IL-1β in patient samples of colitis and in pre-clinical models. Together, these data offer potential new therapeutic angles for targeting toxicity to CICB. Clinical benefit or intestinal toxicity resulting from combined immune checkpoint blockade in patients with melanoma associates with prevalent commensal bacteria and can be decoupled by IL-1R inhibition.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-021-01406-6

Cites

67 of 67 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
Image 2
CC-BY · From the PDF
( P = 0.016 and P = 0.06, respectively; Fig. 4a, Supplementary Table 8 and Extended Data Fig. 6b). We confirmed the concordance of species-level datasets from the 16S and WMS methods by Procrustes analysis (Mantel: r = 0.665, P = 0.001; Extended Data Fig. 6c). In addition, confirmation of bacterial candidates was done using WMS (Fig. 4b and Extended Data Fig. 6d), and a strong positive correlation was observed between the abundance of B. intestinalis quantified using 16S versus WMS (Spearman's ρ = 0.62, P = 4.2 × 10 -6 ,
( P = 0.016 and P = 0.06, respectively; Fig. 4a, Supplementary Table 8 and Extended Data Fig. 6b). We confirmed the concordance of species-level datasets from the 16S and WMS methods by Procrustes analysis (Mantel: r = 0.665, P = 0.001; Extended Data Fig. 6c). In addition, confirmation of bacterial candidates was done using WMS (Fig. 4b and Extended Data Fig. 6d), and a strong positive correlation was observed between the abundance of B. intestinalis quantified using 16S versus WMS (Spearman's ρ = 0.62, P = 4.2 × 10 -6 ,CC-BY · From the PDF
Image 4
CC-BY · From the PDF
Image 5
CC-BY · From the PDF
Extended Data Fig. 1 | See next page for caption.
Extended Data Fig. 1 | See next page for caption.CC-BY · From the PDF
Extended Data Fig. 2 | Fecal microbiome composition and diversity at baseline in CICB-treated patients. a , Stacked bar plot depicting 16S microbial composition of each analyzed fecal sample from the cutaneous and unknown primary cohort at the order level (n = 39). b , c , Comparison of group-wise abundances of Firmicutes ( b ) (p = 0.39) and Clostridiales ( c ) (p = 0.38) by response outcome in the cutaneous/unknown primary cohort (n = 39). d , Inverse Simpson alpha diversity of the fecal microbiome grouped by response in CICB-treated patients with cutaneous or unknown primary melanomas (n = 39) taken at baseline ( p = 0.68, Mann-Whitney test; R = responder, NR = non-responder). Box plots present the median bar with the box bounding interquartile range (IQR) and whiskers to the most extreme point within 1.5 x IQR. All tests are two-sided unless otherwise specified.
Extended Data Fig. 2 | Fecal microbiome composition and diversity at baseline in CICB-treated patients. a , Stacked bar plot depicting 16S microbial composition of each analyzed fecal sample from the cutaneous and unknown primary cohort at the order level (n = 39). b , c , Comparison of group-wise abundances of Firmicutes ( b ) (p = 0.39) and Clostridiales ( c ) (p = 0.38) by response outcome in the cutaneous/unknown primary cohort (n = 39). d , Inverse Simpson alpha diversity of the fecal microbiome grouped by response in CICB-treated patients with cutaneous or unknown primary melanomas (n = 39) taken at baseline ( p = 0.68, Mann-Whitney test; R = responder, NR = non-responder). Box plots present the median bar with the box bounding interquartile range (IQR) and whiskers to the most extreme point within 1.5 x IQR. All tests are two-sided unless otherwise specified.CC-BY · From the PDF
Image 8
CC-BY · From the PDF
Extended Data Fig. 4 | Validation of microbial composition and response taxa across additional datasets. a , Ordination of microbial beta diversity contrasting compositional differences between responders (R, n = 59) and non-responders (NR, n = 24) across the pooled CICB and previously published anti-PD-1 monotherapy (Science 2018) cohorts (Weighted UniFrac, PERMANOVA two-sided p = 0.002). b , Abundance of key response-associated taxa identified in the CICB cohort were evaluated in re-processed microbiome data from several published cohorts, indicating taxa enriched in responders (blue), taxa enriched in non-responders (red), or not detected (white) in each cohort by two-sided Mann-Whitney test ( Ruminococcus; Gopalakrishnan, Science 2018 one-sided p = 0.0240, Frankel, Neoplasia 2017 one-sided p = 0.0487).
Extended Data Fig. 4 | Validation of microbial composition and response taxa across additional datasets. a , Ordination of microbial beta diversity contrasting compositional differences between responders (R, n = 59) and non-responders (NR, n = 24) across the pooled CICB and previously published anti-PD-1 monotherapy (Science 2018) cohorts (Weighted UniFrac, PERMANOVA two-sided p = 0.002). b , Abundance of key response-associated taxa identified in the CICB cohort were evaluated in re-processed microbiome data from several published cohorts, indicating taxa enriched in responders (blue), taxa enriched in non-responders (red), or not detected (white) in each cohort by two-sided Mann-Whitney test ( Ruminococcus; Gopalakrishnan, Science 2018 one-sided p = 0.0240, Frankel, Neoplasia 2017 one-sided p = 0.0487).CC-BY · From the PDF
Image 10
CC-BY · From the PDF
Image 11
CC-BY · From the PDF
Extended Data Fig. 7 | Immune markers of CICB toxicity. a , b , Comparison of Ki67 + cells within CD8 + T effectors (Teff; a ) and T central memory (TCM; b ) cells in early on-treatment blood samples between patients with available blood samples (n = 14) grouped according to high-grade irAE (Mann-Whitney test left panel p = 0.0044, right panel p = 0.013). c , Gating strategy for key CD4/8 + T cell populations. d , e , Percentage of CD28 + cells within CD4 + Teff ( c ) and CD27 + cells within CD8 + Teff ( d ) measured at baseline in this patient cohort (MDACC; left panels) and a separate cohort of patients treated with CICB at Memorial Sloan-Kettering Cancer Center (MSKCC; right panels). Data are grouped by experience of high-grade irAE (Mann-Whitney test ( d ) left panel p = 0.014, right panel p = 0.050 ( e ) left panel p = 0.072, right panel p = 0.32)). f , Boxplot depicting a higher diversity of the peripheral T cell repertoire as measured by TCR V β sequencing in patients experiencing high-grade irAE (n = 24, Mann-Whitney test; p = 0.028). g , Boxplot showing the number of significantly expanded T cell clones (pre- to on-treatment) detected by TCR sequencing of the peripheral blood immune repertoire, grouped by presence or absence of high-grade irAE (n = 16, Mann-Whitney test: p = 0.22). Box plots present the median bar with the box bounding interquartile range (IQR) and whiskers to the most extreme point within 1.5 x IQR. All tests are two sided unless otherwise specified.
Extended Data Fig. 7 | Immune markers of CICB toxicity. a , b , Comparison of Ki67 + cells within CD8 + T effectors (Teff; a ) and T central memory (TCM; b ) cells in early on-treatment blood samples between patients with available blood samples (n = 14) grouped according to high-grade irAE (Mann-Whitney test left panel p = 0.0044, right panel p = 0.013). c , Gating strategy for key CD4/8 + T cell populations. d , e , Percentage of CD28 + cells within CD4 + Teff ( c ) and CD27 + cells within CD8 + Teff ( d ) measured at baseline in this patient cohort (MDACC; left panels) and a separate cohort of patients treated with CICB at Memorial Sloan-Kettering Cancer Center (MSKCC; right panels). Data are grouped by experience of high-grade irAE (Mann-Whitney test ( d ) left panel p = 0.014, right panel p = 0.050 ( e ) left panel p = 0.072, right panel p = 0.32)). f , Boxplot depicting a higher diversity of the peripheral T cell repertoire as measured by TCR V β sequencing in patients experiencing high-grade irAE (n = 24, Mann-Whitney test; p = 0.028). g , Boxplot showing the number of significantly expanded T cell clones (pre- to on-treatment) detected by TCR sequencing of the peripheral blood immune repertoire, grouped by presence or absence of high-grade irAE (n = 16, Mann-Whitney test: p = 0.22). Box plots present the median bar with the box bounding interquartile range (IQR) and whiskers to the most extreme point within 1.5 x IQR. All tests are two sided unless otherwise specified.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

2 retracted

Show all 67 references

Cited by

See all 440

Metadata

Authors
Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., Ferrere, G., Fluckiger, A., Roberti, M. P., Opolon, P., Alou, M. T., Yonekura, S., Roh, W., Spencer, C. N., Curbelo, I. F., Vence, L., Reuben, A., Johnson, S., Arora, R., Morad, G., Lastrapes, M., Baruch, E. N., Little, L., Gumbs, C., Cooper, Z. A., Prieto, P. A., Wani, K., Lazar, A. J., Tetzlaff, M. T., Hudgens, C. W., Callahan, M. K., Adamow, M., Postow, M. A., Ariyan, C. E., Gaudreau, P.-O., Nezi, L., Raoult, D., Mihalcioiu, C., Elkrief, A., Pezo, R. C., Haydu, L. E., Simon, J. M., Tawbi, H. A., McQuade, J., Hwu, P., Hwu, W.-J., Amaria, R. N., Burton, E. M., Woodman, S. E., Watowich, S., Diab, A., Patel, S. P., Glitza, I. C., Wong, M. K., Zhao, L., Zhang, J., Ajami, N. J., Petrosino, J., Jenq, R. R., Davies, M. A., Gershenwald, J. E., Futreal, P. A., Sharma, P., Allison, J. P., Routy, B., Zitvogel, L., & Wargo, J. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Inserm (FR)
  • Institut Gustave Roussy (FR)
  • Parker Institute for Cancer Immunotherapy (US)
  • AstraZeneca (United States) (US)
  • University of Rochester Medicine (US)
  • Memorial Sloan Kettering Cancer Center (US)
  • European Institute of Oncology (IT)
  • Aix-Marseille Université (FR)
  • McGill University Health Centre (CA)
  • Sunnybrook Health Science Centre (CA)
  • Baylor College of Medicine (US)
Corresponding author
  • Zitvogel, Laurence
  • Wargo, Jennifer A.
Venue
Nature Medicine
Published
2021-07-08
Volume
27
Issue
8
Pages
1432-1441
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W3112934313
Cited by
437
References
67
Citations by year
2026: 71 · 2025: 74 · 2024: 77 · 2023: 101 · 2022: 94 · 2021: 19
FWCI
26.77
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion)
  • Research Square (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • HAL (submittedVersion, cc-by)
  • ArTS Archivio della ricerca di Trieste (University of Trieste https://www.units.it/) (submittedVersion, other-oa)
  • HAL (submittedVersion)
Funders
  • U.S. Department of Health & Human Services | NIH | National Cancer Institute (1R01CA219896-01A1)
  • American Association for Cancer Research (SU2C-AACR-IRG-19-17)
  • UT | University of Texas MD Anderson Cancer Center Moonshots Program
  • Department of Health | National Health and Medical Research Council (1148680)
  • U.S. Department of Health & Human Services | National Institutes of Health (T32CA163185, 1 P50 CA221703-02, 1U54CA224070-03, T32 CA 009599)
  • Parcours d’excellence en cancérologie - Fondation Philanthropia
  • University of Texas MD Anderson Odyssey Fellowship Program - Kimberley Clark Foundation Award for Scientific Achievement
  • Fonds de Recherche du Québec - Santé (32667)
  • American Cancer SocietyMelanoma Research AllianceCancer Fighters of Houston
  • Ligue Contre le Cancer
  • Fondation pour la Recherche Médicale
  • Institut National Du Cancer
  • Agence Nationale de la Recherche (10-IAHU-03)
  • Association pour la recherche sur le cancerFondation Carrefour
  • Fulbright France Commission Franco-AmericainéThe John J Kopchick Foundation
  • UT | University of Texas MD Anderson Cancer Center (P30 CA016672)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
gut microbiota, immune checkpoint blockade, CTLA-4, PD-1, immune-related adverse events, melanoma, Bacteroides intestinalis, colitis, IL-1β, T cell receptor repertoire, immune-related toxicity
MeSH terms
Gastrointestinal Microbiome, Animals, Female, Humans, Melanoma, Mice, Inbred C57BL, Cell Line, Tumor, Mice, Interleukin-1beta, CTLA-4 Antigen, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. https://app.cochat.ai/papers/10.1038/s41591-021-01406-6
The paper
Andrews, M. C., Duong, C. P. M., Gopalakrishnan, V., Iebba, V., Chen, W.-S., Derosa, L., Khan, M. A. W., Cogdill, A. P., White, M. G., Wong, M. C., Ferrere, G., Fluckiger, A., Roberti, M. P., Opolon, P., Alou, M. T., Yonekura, S., Roh, W., Spencer, C. N., Curbelo, I. F., . . . Wargo, J. A. (2021). Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nature Medicine. https://doi.org/10.1038/s41591-021-01406-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.